Schizophrenia is a chronic brain disorder with onset in the second to third decades of life that affects as much as 1% of the population around the world. It is characterized by profound disruption of the most fundamental human attributes: language, thought, perception, cognition, emotion and sense of self.
- There are 28 million schizophrenia patients worldwide requiring chronic lifelong treatments
- US healthcare spends ~ $30 billion annually on the disease
- Significant unmet needs: existing medications have little impact on functional outcome
- Functional outcomes are driven by cognition and social functioning; existing medicines have limited benefit on cognition and social functioning
- Medication non-compliance is a barrier to functional outcome; existing medications have significant side effect profiles which drive non-compliance
- New technologies are driving new development of drugs with efficacy functional impacts and fewer side effects